Pharma returns on R&D ebb to new low, Deloitte finds

Deloitte's annual report on R&D productivity, while limited in scope, is an indicator of the challenges faced by large pharmaceutical firms in bringing new...

Sanofi inks research deal with Denali in neurological, inflammatory diseases

Denali started 2018 with one research agreement with Takeda and is now ending the year with another big pharma collaboration. The Takeda deal, announced in January,...

Pharma returns on R&D ebb to new low, Deloitte finds

Deloitte's annual report on R&D productivity, while limited in scope, is an indicator of the challenges faced by large pharmaceutical firms in bringing new molecules...

Rival accuses Kaleo of cybersquatting in ‘elaborate scheme’

Cybersquatting was most common in the 1990s and early 2000s, with someone snatching a domain and then selling it to the trademark holder for...
Array's combination of Braftovi (encorafenib) and Mektovi (binimetinib) already appears well received in the small clinical setting of advanced melanoma with BRAF V600E or...
Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 
"It could become very challenging for a small biotech company, or even a pharma company, to cover that part of a clinical trial test,"...

Follow RXMonthly

News

Lilly to withdraw FDA-approved cancer drug after clinical failure

Lartruvo (olaratumab) was the first new drug approved for soft tissue sarcoma in more than four decades, at the time offering patients with the...

Amgen bone drug application knocked back in Europe

Expectations for Evenity (romosozumab) are modest, and the rejection by the EMA is a "minor setback" for Amgen, according to RBC Capital Markets analyst...

Safety setback for Pfizer, Lilly pain drug should have...

The U.S. opioid crisis breathed new life into clinical development of the nerve-growth factor (NGF) inhibitors tanezumab and fasinumab. The drug class had been...

No news is bad news for Tocagen

Brain cancers are among the most difficult to treat, as Tocagen's struggles follow late-stage study failures earlier this month from AbbVie and Bristol-Myers Squibb. The...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter